Archive for the ‘clinical study retractions’ Category
The abstract, “Reduced syntaxin-5 in skeletal muscle of patients with type 2 diabetes is linked to increased diacylglycerol, activation of PKCtheta and impaired insulin signalling,” was presented at the annual meeting of the European Association of the Study of Diabetes. The first author was Kurt Højlund, who now is at the University of Southern Denmark. The second author was Pontus Boström, of the Karolinska Institutet.
The paper, “Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis“, came from a group at Harvard, Weill Cornell and the University of Athens. The authors purported to find that: Read the rest of this entry »
The article, “The complications of repeat median sternotomy in paediatrics: six-months follow-up of consecutive cases,” came from a team at Glenfield Hospital in Leicester, England, and has been cited eight times, according to Scopus.
Here’s the notice:
After our post yesterday on a fishy retraction from author Brian Peskin, a reader who alerted the journal to problems got in touch to give us the lowdown.
The Journal of Lipids has retracted an aggressively negative review article called “Why Fish Oil Fails,” written by one Brian S. Peskin, whose bogus health claims have landed him in plenty of hot water in the past.
Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.
Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.
The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Read the rest of this entry »
Update, 4 p.m. EST, 10/29/14: As a commenter points out, we didn’t quite get this one right. The Boldt paper that has been retracted was not previously retracted for lack of IRB approval. Rather, it was a heretofore unretracted article, from 1996, which German investigators have determined contained faked data. We’ve made edits below using strikethroughs, and have changed the headline to better reflect the content. We apologize for the errors.
We’ve commented before on the fact that we’ve noticed there’s often more to retractions whose stated reason is lack of institutional review board (IRB) approval. We can understand editors’ inclination to act as quickly as possible to issue a retraction, the scientific publishing equivalent of jailing Al Capone for tax evasion. But we appreciate it even more when said editors return to the scene of the crime, as it were, when new important details come out.
Case in point: Anesthesia & Analgesia has amended its retraction of a
2009 1996 study by Joachim Boldt — who with nearly 90 retractions once held the record in that department — based on findings that the data in that paper were fabricated.
The article was titled
“Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy,” “The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patient.” had previously been retracted because Boldt had failed to obtain adequate ethics approval for the research. But now comes this, According to the retraction notice from editor in chief Steven Shafer: Read the rest of this entry »
Dentists Bryan and Paul Jacobs, a father and son team, wrote a paper describing a novel surgical technique in March 2013. In October 2013, several Croatian dentists published their own paper using the technique.
A year later, the story has gotten a little more interesting. The November issue of the Journal of Oral and Mixillofacial Surgery, which published the second article, has two letters. One, from the Jacobses, accuses the Croatian authors of plagiarism. The second is a response from author Dragana Gabrić Pandurić, claiming “our real intention was to emphasize, not plagiarize, their work.”
On Monday, we were first to report that a study of green coffee bean extract for weight loss touted on the Dr. Oz Show had been retracted.
Two authors of a 2012 paper sponsored by a company that made grand claims about green coffee bean extract’s abilities to help people lose weight have retracted it. The study was cited by The Dr. Oz Show, and last month it cost the company a $3.5 million settlement with the Feds.
Here’s the notice for “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” a paper originally published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: Read the rest of this entry »